Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Hospital Duran i Reynals
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital Duran i Reynals (28)
2023
2022
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
2020
-
Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 4
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer
International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 1050-1056
-
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1141-1147
2018
-
Correction to: SEOM clinical guidelines for endometrial cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (29-37), 10.1007/s12094-017-1809-9)
Clinical and Translational Oncology
-
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781
-
SEOM clinical guidelines for endometrial cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 29-37
-
The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism
Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 230-242
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
2015
-
SEOM guidelines for cervical cancer
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1036-1042
2014
-
Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels
Journal of Hematology and Oncology, Vol. 7, Núm. 1
2013
-
A prognostic DNA methylation signature for stage I non-small-cell lung cancer
Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952
2012
-
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours
Scientific Reports, Vol. 2
2011
-
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma
Leukemia Research, Vol. 35, Núm. 4, pp. 431-437